4967 — Kobayashi Pharmaceutical Co Balance Sheet
0.000.00%
- ¥416bn
- ¥346bn
- ¥166bn
Annual balance sheet for Kobayashi Pharmaceutical Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 109,046 | 104,533 | 79,836 | 65,745 | 70,614 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 55,147 | 47,853 | 52,984 | 49,384 | 52,135 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 181,889 | 172,892 | 158,331 | 144,468 | 148,820 |
| Net Property, Plant And Equipment | 22,524 | 34,778 | 47,665 | 67,448 | 67,367 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 252,554 | 255,827 | 267,473 | 265,368 | 275,329 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 50,703 | 51,809 | 56,111 | 46,423 | 60,137 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 56,954 | 57,927 | 62,657 | 51,901 | 64,330 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 195,600 | 197,900 | 204,816 | 213,467 | 210,999 |
| Total Liabilities & Shareholders' Equity | 252,554 | 255,827 | 267,473 | 265,368 | 275,329 |
| Total Common Shares Outstanding |